Search results
23andMe is low on cash and its stock is worth pennies. The CEO wants another chance
CNN Business via Yahoo Finance· 3 months agoJust three years ago, DNA testing company 23andMe was the golden child of Wall Street and Silicon...
23andMe Holding Co.'s (NASDAQ:ME) Share Price Could Signal Some Risk
Simply Wall St. via Yahoo Finance· 1 year agoWhen you see that almost half of the companies in the Healthcare industry in the United States have...
23andMe's share price keeps on falling in the wake of hacks and losses
Business Insider via Yahoo Finance· 3 months ago23andMe CEO Anne Wojcicki.Steve Jennings/Getty Images/TechCrunch 23andMe stock is down over 95% from...
23andMe CEO Says Company Is Doing Fine Despite Losing 93% of Stock Value
Futurism via Yahoo News· 3 months agoThe consumer genome sequencing company 23andMe is a sinking ship – and their CEO is playing the...
Billionaires Are Snapping Up Beaten-Down 23andMe Stock. Should You Follow Their Lead?
Motley Fool via Yahoo Finance· 1 month agoIf you're an individual investor who wants to invest like a billionaire fund manager, I've got good...
23andMe Stock Slides After DNA-Testing Company's Disappointing Results
The Wall Street Journal· 3 months agoDNA-testing company 23andMe said late Wednesday that it was considering splitting itself in two, one...
23andMe Holding Co. (NASDAQ:ME) Q3 2024 Earnings Call Transcript
Insider Monkey via Yahoo Finance· 3 months ago23andMe Holding Co. (NASDAQ:ME) Q3 2024 Earnings Call Transcript February 7, 2024 23andMe Holding...
23andMe Holding (NASDAQ:ME) shareholders have endured a 41% loss from investing in the stock a year...
Simply Wall St. via Yahoo Finance· 1 year agoPassive investing in an index fund is a good way to ensure your own returns roughly match the...
One 23andMe Holding Co. (NASDAQ:ME) insider upped their stake in the previous year
Simply Wall St. via Yahoo Finance· 2 years agoLooking at 23andMe Holding Co.'s (NASDAQ:ME ) insider transactions over the last year, we can see...
Better AI Biotech Stock: Recursion Pharmaceuticals vs. 23andMe
Motley Fool· 8 months agoRecursion Pharmaceuticals (NASDAQ: RXRX) and 23andMe (NASDAQ: ME) are both popular biotech stocks...